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Background: Accurate determination of Schistosoma infection rates in low endemic regions to examine progress
towards interruption of transmission and elimination requires highly sensitive diagnostic tools. An existing lateral
flow (LF) based test demonstrating ongoing infections through detection of worm circulating anodic antigen (CAA),
was improved for sensitivity through implementation of a protocol allowing increased sample input. Urine is the
preferred sample as collection is non-invasive and sample volume is generally not a restriction.
Methods: Centrifugal filtration devices provided a method to concentrate supernatant of urine samples extracted with
trichloroacetic acid (TCA). For field trials a practical sample volume of 2 mL urine allowed detection of CAA down to
0.3 pg/mL. The method was evaluated on a set of urine samples (n = 113) from an S. mansoni endemic region (Kisumu,
Kenya) and compared to stool microscopy (Kato Katz, KK). In this analysis true positivity was defined as a sample with
either a positive KK or UCAA test.
Results: Implementation of the concentration method increased clinical sensitivity (Sn) from 44 to 98% when moving
from the standard 10 μL (UCAA10 assay) to 2000 μL (UCAA2000 assay) urine sample input. Sn for KK varied between 23
and 35% for a duplicate KK (single stool, two slides) to 52% for a six-fold KK (three consecutive day stools, two slides).
The UCAA2000 assay indicated 47 positive samples with CAA concentration above 0.3 pg/mL. The six-fold KK detected
25 egg positives; 1 sample with 2 eggs detected in the 6-fold KK was not identified with the UCAA2000 assay.
Conclusions: Larger sample input increased Sn of the UCAA assay to a level indicating ‘true’ infection. Only a single
2 mL urine sample is needed, but analysing larger sample volumes could still increase test accuracy. The UCAA2000
test is an appropriate candidate for accurate identification of all infected individuals in low-endemic regions. Assay
materials do not require refrigeration and collected urine samples may be stored and transported to central test
laboratories without the need to be frozen.
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Interruption of transmission of Schistosoma infections
and potential elimination is thought feasible as highlighted by
the commitment of the 65th World Health Assembly [1].
Several approaches are being evaluated to develop methods to
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unless otherwise stated.improved sanitation and availability of clean water, as well as
snail control [2-6]. To monitor the effect of these efforts, and
to identify remaining pockets of infection, highly accurate
diagnostics are obligatory especially for identification of indi-
viduals with very low levels of infection [7-10]. In most popu-
lations, serology (antibody detection) is not the appropriate
method to detect active infections as it will also indicate past
infections [11,12]. Detection of the presence of living worms
can be done by showing schistosome eggs, nucleic acid, or an-
tigens in different human samples. Importantly, one needs toal. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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require to clear these components from the human
body after drug treatment. Excretion of schistosome
eggs continues for weeks [13] and therefore does not
allow a diagnosis of the efficiency of treatment shortly
after drug administration; much more rapidly cleared
circulating schistosome-antigens in that respect present
a better potential [14-16].
Since many years, the still widely applied method to
diagnose active infection in low resource settings is
detection of eggs in urine (S. haematobium) or stool
(S. mansoni and S. japonicum), although this method
is elaborate and lacks sensitivity [17]. For intestinal S.
mansoni infections, a point-of-contact rapid urine-
based antigen test (POC-CCA; Rapid Medical Diagnostics,
Pretoria, RSA) is available which is based on the detection
of a worm regurgitated antigen (circulating cathodic anti-
gen, CCA). The sensitivity of the POC-CCA test has been
reported to be better than or equivalent to stool egg counts
based on a triplicate Kato-Katz analysis [18]. In case of
S. haematobium, causing urogenital schistosomiasis, po-
tential infections are indicated by microhematuria lead-
ing to small amounts of blood in the urine detectable
with a rapid dipstick test [19]. Note that specificity of
latter test for schistosomiasis is inadequate as it cannot
rule out other urinary-tract infections. More importantly,
urine POC-CCA and microhematuria dipstick are not
sensitive enough to determine true prevalence of infection
in near-elimination settings where transmission appears to
be interrupted. Also, prevalence based on egg counts is
expected to significantly underestimate true infection rates
as illustrated by the statistical model of de Vlas et al. [20].
A highly sensitive and increasingly applied method to de-
tect pathogen infections is by means of PCR, detecting nu-
cleic acids. This has been demonstrated using urine and
stool samples for the major human Schistosoma infections
[21-25] and has excellent multiplex capability (simul-
taneous screening for and detection of multiple infec-
tions/pathogens). However, this technology is very
expensive and not readily available for resource limited
setting and remote areas. Moreover, nucleic acid based
assays mostly detect egg DNA and similar to egg counts
have some limitation in testing effects of drugs shortly
after administration.
Earlier described antigen assays have demonstrated to
be well suited for detection of active infections (see refs
in Corstjens et al. [26]). Initial ELISA formats have been
converted to user-friendly lateral-flow based assays
[27,28]. The POC-CCA urine strip test is the only com-
mercially available lateral flow test applied for routine
detection of S. mansoni infections. Although for low en-
demic settings the sensitivity is still too low, the test is
well suitable as a mapping tool and appropriate for
monitoring and evaluation in schistosomiasis controlprogrammes [18] as an alternative for microscopic stool
analysis. Another, more advanced antigen test detects
the Schistosoma circulating anodic antigen (CAA). The
in this study described CAA test is genus-specific
allowing detection of all Schistosoma species including
veterinarian (see references in Corstjens et al. [26]). As
an assay, it has a somewhat higher complexity which
mainly relates to a sample pretreatment step, an extrac-
tion with trichloroacetic acid (TCA) followed by a
centrifugation step. The resulting clear supernatant con-
taining the targeted CAA (a carbohydrate structure) is
then analysed on a LF strip utilizing a unique fluorescent
reporter, upconverting phosphor (UCP) particles [29]. A
previously developed, robust, user-friendly dry-reagent
format of the UCP-LF CAA assay [30] allowing con-
venient shipping and storage at ambient temperature,
has already been utilised by local staff in different
laboratories around the world [26,31-33]. In the current
study we demonstrate further improvement of the sensi-
tivity of the UCP-LF CAA assay by including a concentra-
tion step in the sample pretreatment protocol as proposed
previously [26]. This step involves the concentration of
the TCA-soluble fraction of urine samples using Amicon
Ultra Centrifugal Filter Devices (Millipore Corp.), allow-
ing larger sample input, increasing the volume from 10
μL urine to 250 and 2000 μL, or even 7500 μL. The
results confirm that the larger sample input identified
samples with CAA concentrations well below the 30 pg/
mL cutoff threshold as maintained for the standard dry-
reagent UCP-LF CAA assay without concentration and
requiring only 10 μL urine (UCAA10) [26]. For the sam-
ple set tested in this study, when using the 2000 μL urine
concentration assay (UCAA2000) the prevalence in-
creased to the level that would be predicted based on
eggs detected in stool samples following the model of de
Vlas et al. [20].
Methods
Ethics statement
This study was reviewed and approved by the scientific
steering committee and the national ethics review com-
mittee of the Kenya Medical Research Institute. Parents
of minors provided written informed consent and mi-
nors provided written assent to participate in the study.
All positive cases were treated appropriately.
Study site
Samples were collected from a village near Kisumu,
Western Kenya, along the shores of Lake Victoria
where only intestinal schistosomiasis is endemic. There
were no records or other indications for urogenital
schistosomiasis. Previous screenings for microhaema-
turia always showed less than 2% positives for potential
urinary tract infections.
Figure 1 UCAA test results of corresponding urine samples stored
frozen or at ambient temperature. Upper panel: scatter plot showing
the Pearson correlation of the UCAA2000 assay results presented
as ratio value (T/FC). Lower panel: Spearman ranking of the samples
also based on T/FC ratio value.
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Participants were provided with stool containers and
asked to provide fresh stool samples on three consecu-
tive days. Samples were transported to the KEMRI/CDC
laboratory where they were processed and examined
using the Kato-Katz technique [34] for detection of
parasite eggs, two slides (42 mg) per stool. Internal qual-
ity control was achieved by having different microsco-
pists reading both slides, with each technician blinded to
the other corresponding stool result. The arithmetic
mean of egg counts was calculated from the total slides
per child, and expressed as eggs per gram (epg).
Collection of urine specimens and storage
On day one of the stool collection, fresh morning mid-
stream urine was collected from school children into clean
pre-labelled tubes to ensure it was free from any contami-
nants. Hematuria, indicating potential S. haematobium
infection, was determined using URiSCAN test strips (YD
Diagnostics, Kyunggi-Do, Korea). Urine samples were
split, one part stored at −20°C and the other part stored at
ambient temperature for three weeks and transported to
IPR (Nairobi) where they were tested with the dry-reagent
UCP-LFCAA assays (UCAA10, UCAA250 andUCAA2000).
UCP-LF CAA assays
For the standard UCAA10 assay, urine samples were ex-
tracted with an equal volume of 4% w/v TCA as de-
scribed previously [28]. Of the resulting TCA-soluble
fraction (TCA-supernatant, consisting of 50% v/v urine,
2% w/v TCA), 20 μL was added to a tube containing 100
ng of dry CAA-specific UCP reporter (400 nm Y2O2S:
Yb3+,Er3+ particles [29] coated with mouse monoclonal
anti-CAA antibodies) hydrated in 100 μL assay buffer
(100 mM HEPES pH 7.5, 270 mM NaCl, 0.5% v/v
Tween-20, 1% w/v BSA) [30]. Tubes were incubated for
60 min at ambient temperature (25–30°C) in an orbital
shaker (900 rpm); note that the standard protocol indi-
cated incubation at 37°C [30]. Next, immunochromato-
graphy was initiated by placing a CAA-specific LF strip
[28] in the tube and LF allowed to continue until strips
were dry. LF strips were analysed using a lightweight
portable UCP scanner (UCP-Quant [35,36]; QIAGEN
Lake Constance GmbH, Stockach Germany). Test line
signals (T) were normalized to flow control signals (FC)
of the individual LF strips and results expressed as a ra-
tio value (T/FC) [37,38]. Serial dilutions, prepared in
normal human urine (NHU), of TCA-soluble fraction of
Schistosoma adult worm antigen (AWA-TCA; containing
3% w/w CAA [26]) were analysed in parallel to provide
standard curves for calculation of the CAA concentra-
tions in the clinical samples.
For the UCAA250, −2000 and −7500 concentration
assays, 500, 4000 or 15000 μL TCA-supernatant wasconcentrated to 20 μL using 0.5, 4, and 15 mL centrifu-
gal filter devices (Amicon Ultra-0.5, −4, −15 Centrifugal
Filter Devices; Millipore Corp.), respectively. The concen-
trates were then processed as described for the UCAA10
assay.
The during production maintained quality control
(QC) thresholds for the dry-reagent UCP-LF CAA
assays were 30, 3, 0.3 and 0.1 pg CAA per mL urine for
the UCAA10, −250, −2000 and −7500 assay, respectively
[26]. An indecisive range was defined of 30–15, 3–1.5,
0.3-0.15 and 0.1-0.05 pg/mL, respectively (note that in-
house at LUMC, UCP-LF CAA assays may be performed
with wet UCP reagents which require a sonication step
but have a 3-fold better analytical sensitivity [26]).
Clinical samples generating test results with CAA
concentrations falling in the indecisive range are po-
tentially positive, but if interpreted as negative would
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the lower value of the indecisive range are identified as
negatives. The UCAA7500 assay was not included in the
testing of the clinical set of urine samples.
Results and discussion
Stability of the CAA in urine
Previous testing in our laboratory indicated that storage
conditions of the urine samples did not require highly con-
trolled conditions (unpublished). CAA concentrations were
not different in matching urine samples that were stored
either at ambient temperature for a few weeks, refrigeratedFigure 2 Effect of increased sample input on the LLOD of the UCP-LF CAA
in upper panel), analysed in triplicate with the UCP-LF wet assay format. S
TCA-supernatant was either tested directly with the UCAA10 assay or first con
in the lower panel (a blow up of the y-axis) indicate the QC cutoff threshold f
bars indicate 1 standard deviation (n = 3).at 4°C for several months, or frozen at −20°C for years. The
current study included storage of a small set (n = 18) of
urine samples at ambient temperature (25–35°C) for 3
weeks, compared to storage in the freezer (−20°C). This
three weeks period was chosen as it would allow conveni-
ent collection of urine samples in field experiments with
subsequent transport to central laboratories without the
need for a cold chain. Prior to use, (thawed) urine sam-
ples were mixed with an equal volume of 4% (w/v) TCA.
Precipitates and any other particulate material in this
mixture are removed by centrifugation; note that this
step also takes care of potential precipitates formed as aassay. AWA-TCA standard series in urine (CAA concentration indicated
piked urine was extracted with 1 volume 4% (v/v) TCA, the resulting
centrated using 0.5, 4, and 15 mL Amicon centrifugal filter devices. Arrows
or the different assays; left to right: UCAA10, −250, −2000 and −7500. Error
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the CAA concentrations for the two storage conditions
as a Pearson correlation (upper panel) and a Spearman rank-
ing scattergram (lower panel). CAA levels are determined
with the UCAA2000 assay and arbitrarily expressed by
UCP-LF assay values (T/FC ratio). The good association
of this small set indicates high stability of the CAA com-
ponent in urine samples kept at ambient temperature for
several weeks which may allow simplified sample storage
and shipping conditions.
Implementation of concentration devices – improved
limit of detection
The standard UCP-LF CAA assay for urine (UCAA10)
allows testing of 20 μL TCA-supernatant (50% v/v urine,
2% w/v TCA) with a pre-determined QC cutoff thresh-
old of 10 or 30 pg CAA per mL, respectively for the
wet- and dry-reagent format. To improve the lower limit
of detection (LLOD), TCA-supernatant was concen-
trated using centrifugal filter devices. Assuming a single
load protocol (meaning that the Amicon concentration
devices were loaded ‘only’ once with the indicated max-
imum capacity), the assessed 0.5, 4 and 15 mL centrifu-
gal devices theoretically would allow a 25-, 200- and
750-fold concentration, respectively. A standard series of
AWA-TCA in NHU was analysed in triplicate with the
UCAA10, −250, −2000 and −7500 using a freshly soni-
cated stock solution of UCP reporter particles (referred
to as wet assay format [28]). For this format, the LLOD
detection of CAA in urine progressed from 10 pg/mL
to 0.03 pg/mL when increasing urine sample input
from 10 μL to 7.5 mL; a practical improvement by 50%
of the theoretical limit (Figure 2). Similar factors were
achieved with the dry-reagent assay (UCP particlesFigure 3 CAA standard series in urine analysed with the UCP-LF concentra
250 to 2000 μL, respectively for the UCAA10, −250 and −2000 assay. The U
using Amicon Centrifugal Filter Devices Ultra-0.5 and Ultra-4, respectively.supplied as a dry pellet [30]). When using the UCAA7500
assay, 15 mL TCA-supernatant (containing 7.5 mL urine)
is first concentrated to 500 μL with a 15 mL centrifugal fil-
tration device and then transferred to a 0.5 mL centrifugal
device for further concentration to 20 μL. The approxi-
mate centrifugation time required for the different devices
is 15, 30 and 60 minutes for the 10 kDa molecular weight
cutoff filtration devices used in this study.
Analysis of the S. mansoni Kisumu urine set with UCP-LF
CAA assay
The urine samples collected in Kisumu were tested at
IPR (Nairobi) with the UCP-LF dry-reagent assay. These
assay materials were transported from the Netherlands
to Kenya without cooling, and on arrival stored at ambi-
ent temperature. Not needing a cold chain for shipping
was an important feature that reduced cost and logistic
issues. All 113 samples were tested (in singlet) with the
UCAA10 and −250 assay. However, material restrictions
only allowed testing of 73 samples with the UCAA2000
assay. Scanning of the LF strips and analysis of the result
was also performed at IPR utilizing a lightweight reader
with appropriate software as described for other studies
[35]. CAA concentrations were determined from stand-
ard curves obtained with NHU spiked with AWA-TCA
tested with the UCAA10, −250 and −2000 assay (Figure 3)
using a 4 parameter curve fit method. Samples were
classified as positive, indecisive or negative according the
predetermined QC cutoff thresholds. The number of
CAA positives increased from 21 (identified with the
UCAA10 assay) to 30 when using the concentration
based assays UCAA250. In the subset of 73 samples that
were tested with all 3 UCAA assays, the number of
CAA positives increased from 15 in the UCAA10, to 20tion assays. The amount of urine analysed per strip increased from 10,
CAA250 and UCA2000 require concentration of the TCA-supernatant
Table 1 Effect of increased sample input on the number of CAA positives
Assay resulta UCAA10 UCAA250 UCAA10 UCAA250 UCAA2000
Positive 21 (19%) 30 (26%) 15 (19%) 20 (28%) 31 (43%)
Indecisive 6 (5%) 1 (1%) 6 (5%) 1 (1%) 3 (4%)
Negative 86 (76%) 82 (73%) 52 (71%) 52 (71%) 39 (53%)
Samples testedb 113 113 73 73 73
aNumbers represent the amount of samples with a specific test result (between brackets as the percentage of total number of samples tested).
bThe Kisumu sample set comprised urine samples of 113 individuals which were tested with the UCAA10 and UCAA250 assay. A non-random subset of 73 samples
was also tested with UCAA2000 assay (not included in this subset were 10 samples that scored a positive test result with both, UCAA10 and UCAA250, plus 30
samples that scored a negative test result with the UCAA250).
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Increased sample volume obviously did result in an
increase of the number of identified CAA positives,
raising the percentage positives in the (non-random)
subset from 19%, to 27%, to 42% for the respective
assays (Table 1). Moreover, positives identified by the
UCAA10 assay were all confirmed with the UCAA250
assay, and similarly from the UCAA250 assay to the
UCAA2000 assay. Out of the 6 UCAA10 indecisive
samples 50% was a true positive as demonstrated with
the larger sample volume assay (UCAA250). The single
sample classified indecisive with the UCAA250 did not
test positive with the UCAA2000 assay. We speculate
that the percentage of indecisive samples that actually
turn out positive may vary per setting. The pre-determined
QC cutoff thresholds firmly maintain 100% specificity.
Depending on the objective of the study, when targetingFigure 4 Expected qualitative UCAA2000 test results for samples tested wi
with both the UCAA10 and UCAA250 assay. Only a non-random subset (n = 7
assay. The subset included 52 samples with a negative UCAA250 result. Ten sa
samples with a negative test result for the UCAA250 were excluded. Extrapola
assumed as empirically determined for the 52 negatives tested with the UCAA
test result; (+) and (−) following the UCAA assay indicate a positive or negativ100% sensitivity the indecisive group should be included in
the positive group.
Note that the subset of 73 samples does not represent
an absolute random selection of the full Kisumu set. The
subset did not include 30 out of 82 samples that had
tested negative with the UCAA10 and UCAA250 assay.
Also not included were 10 out of 21 positive samples that
demonstrated high reactivity with both the UCAA10 and
−250 assay and undoubtedly would return a positive test
result with the UCAA2000 (Figure 4).
Kato Katz analysis of the S. mansoni stool set
Stool samples collected at three consecutive days were
analysed in duplicate at KEMRI/CDC (Kisumu, Kenya).
Egg counts were quantified on two slides of 42 mg per
stool per day as described by Katz el al. [34], resulting
in 6 KK counts per individual; Table 2 summarizes theth UCAA10 and UCAA250. The Kisumu sample set (n = 113) was tested
3; selection based on UCAA10/250 results) was tested with the UCAA2000
mples with a positive test result for both UCAA10 and UCAA250, plus 30
tion: for the 30 negatives, the same percentage of positives (21%) was
2000 assay. Numbers between brackets indicate samples with a negative
e test result, respectively.
Table 2 Kato Katz analysis, two slides per stool on
3 stools collected on consecutive days
Day 1 Day 2 Day 3 Day 1-3
Assay resulta KK1-2 KK3-4 KK5-6 KK1-6b
KK egg positive 17 (15%) 13 (12%) 12 (11%) 25 (22%)
KK egg negative 96 (85%) 100 (88%) 101 (89) 88 (78%)
Samples tested 113 113 113 113
aNumber of individuals with/without eggs; between brackets the percentage
of samples with a specific test result considering testing the complete
collection (positive egg result indicates prevalence of infection by KK).
bTotal number of individuals with eggs; identified an egg in at least one out of
six slides.
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consecutive days, resulting in prevalences ranging from
11-15% per day, with 22% for the 3x2 KK results (25 egg-
positive cases). The number of eggs counted per duplicate
KK (84 mg stool) varied between 2 to 14 eggs, i.e. 24 to
168 epg, a universal finding for low endemic regions. Of
the 25 egg positives, 16 were identified with the UCAA10
assay, and 18 with the UCAA250. The UCAA2000 assay
was applied on a subset containing 17 of the 25 egg posi-
tives, and identified 16 out of these positive. Hence, using
the predetermined UCAA2000 QC cutoff threshold (a
CAA level of 0.3 pg/mL), 1 egg positive (2 eggs identified
in only one of the three duplicate KK, translating to just 8
epg) was missed. Using the concentration based assay in
our laboratory on well documented banked samples (un-
published results), no egg positives were missed when test-
ing serum (500 μL serum, SCAA500 [26]). When testing
larger urine sample collections with the UCAA2000 assay,
the ‘failure rate’ never exceeded 5% including potential ad-
ministrative error.
Definition of a gold standard and clinical specificity
Similar to the approach defining a composite reference
standard as recommended by WHO/TDR [39], in this
study true positives are defined as being positive in KKTable 3 Clinical sensitivity and prevalence for UCP-LF assays
Kisumu set: N = 113 True positivesa Fal








aThe Gold Standard positive is defined as a sample (stool or paired urine) with at le
urine as determined with the UCAA2000 assay.
bFalse negatives are defined against the Gold Standard and calculated by ‘False Ne
cNumber of UCAA2000 positives (including 16 additional positives, Figure 4).and/or the UCAA2000 assay (note: ten samples positive
for both, UCAA10 and UCAA250, were not tested with
larger sample volume but counted as UCAA2000 posi-
tive). Targeting 100% specificity, samples identified as
UCAA2000 indecisive (potential CAA levels between
0.1 and 0.3 pg/ml) are interpreted as negatives. Calcula-
tion of the clinical sensitivity and prevalence of the full
sample set (113 samples) required extrapolation to
obtain a qualitative UCAA2000 test result for the 30
UCAA250 negatives which could not be tested with the
UCAA2000 assay. The extrapolation was based on the
UCAA2000 assay result obtained with 52 UCAA250
negatives (a random selection from all 82 UCAA250 neg-
atives in the full set of 113 samples) of which 11 samples
(21%) returned a positive test result in the UCAA2000,
thus predicting 6 additional positives in the set of 30
(Figure 4). Moreover, 10 additional samples with both, a
positive UCAA10 and UCAA250 result, but not tested with
the UCAA2000 assay were also regarded as UCAA2000
positive (Figure 4). Table 3 shows the sensitivity and preva-
lence determined for the 113 samples that were tested with
the KK and the UCP-LF CAA assays (UCAA10, UCAA250
and UCAA2000). According to the above defined gold
standard the Kisumu set (n = 113) contained 48 true posi-
tives. This number includes 17 CAA positives identified
with the UCAA2000 assay that were negative with the
UCAA250 and UCAA10, and 1 egg positive identified only
by detection of two eggs in one out of six slides. As indi-
cated by the presence of samples generating a UCAA2000
indecisive result, it might be possible that with a further in-
crease of the sample volume (for instance using the
UCAA7500 assay) a few more positives could be identified.
The 17 samples identified by UCAA2000 only, indicated
CAA levels in the range of 0.3 to 3 pg/mL. It is yet un-
known what level of CAA in urine can be expected for in-
dividuals infected by single worm pair, but we note that the
currently maintained UCAA2000 lower detection level of
0.3 pg/mL CAA in urine is >10-fold lower in comparisonand KK analysis









ast a single egg in the 6-fold KK stool analysis or a CAA level > 0.3 pg/mL in
gatives = 48 – True Positives’.
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infection by a single worm (see references in Corstjens
et al. [26]). According to the model by de Vlas et al. [20],
based on KK egg count the true prevalence would be in the
40-60% range; the UCAA2000 assay with a prevalence of
41.6% falls within that range. In addition, the use of larger
concentration devices allows convenient confirmation of
the positives through analysis of larger sample volumes. It
is important to note that the various UCP-LF assays require
only a single urine sample for analysis, whereas accurate
identification by KK requires analysis of multiple stool
samples, which puts heavy logistical demands on national
mapping programmes and may reduce compliance consid-
erably. Compared to egg positives identified by KK, the dif-
ference is obvious: 41.6% positives for the UCAA2000
assay requiring only a single urine sample, versus 22.1%
positives for the 6-fold KK analysis on three consecutive-
day stool samples. A single stool duplicate KK (2 slides)
showed a prevalence as low as 9.7%, less than half of what
was found by the UCAA10 (using 10 μL urine, not requir-
ing a concentration device). The 26.5% prevalence deter-
mined with UCAA250 assay was already significantly
higher than the prevalence with the 6-fold KK, both indi-
cating the value and efficacy of the UCP-LF CAA assay.
In this study, the urine UCP-LF CAA assays showed to
be highly superior in clinical sensitivity compared to KK.
Using larger sample volumes increased the number of
CAA positive samples from 21 for the UCAA10 assay (10
μL urine) to 30 for the UCAA250 assay (250 μL urine), to
47 for the UCAA2000 assay (2,000 μL urine). Before this
test could claim ‘gold standard’ status, more investigation
is required with a focus on samples generating a UCAA
negative result with a positive KK result (in this study ap-
plying to only a single case). Administrative errors at any
stage of the sampling and testing cannot be excluded, and
therefore retesting requiring follow-up sample collection
(possibly including serum) is necessary to unequivocally
confirm discrepant results with KK and any other test.
Conclusions
The UCP-LF CAA assay to identify active Schistosoma in-
fections utilizing urine samples demonstrated excellent
sensitivity. Analysis of a single 10 μL urine sample clearly
demonstrated superiority to a duplicate KK performed on
a single stool sample: 19% versus 10-15% prevalence re-
spectively for UCP-LF (UCAA10) and KK. The implemen-
tation of a concentration step allowed 200-fold larger
sample input (UCAA2000) which further improved CAA
detection sensitivity from 30 pg/mL to 0.3 pg/mL reaching
a prevalence of 42% while maintaining specificity at 100%.
As the test is genus specific and has the highest demon-
strated sensitivity showing infection levels similar to the
true prevalence predicted by the statistical model of de
Vlas et al. [20], the UCP-LF CAA concentration assay forurine is a very attractive alternative for egg count assays
(stool and/or urine) especially in low endemic settings ap-
proaching interruption of transmission and elimination of
schistosomiasis. Moreover, the non-invasive one-stop sam-
ple collection, omission of a cold-chain for assay reagents
(shipping and storage) and expectedly also for the collected
urine samples, are desirable features for acceptance and
implementation of the assay in resource limited settings.
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